For example, the amplification of FGF receptor 2 (FGFR2), which is less frequent than the amplification of FGF receptor 1 (FGFR1) across cancer types, is often reported in patients with gastric-esophageal junction adenocarcinoma (39). This evidence concerns the gene FGFR1 and cancer.